Home » Newsletters » BioWorld Science

BioWorld Science

June 16, 2004

View Archived Issues

Biliverdin protective against endotoxin-induced acute lung injury

Human serpin with potential to heal diabetic ulcers

Increased survival achieved with efaproxiral in patients with brain metastases

Preliminary data suggest epratuzumab plus rituximab is safe and effective in NHL

Phase I data on XR-5944 in patients with refractory advanced cancer

Peripheral efficacious kappa opioid agonist with unprecedented selectivity

Aptosyn phase III study in NSCLC fails to meet endpoints

Teva and Active Biotech sign laquinimod licensing deal

FDA agrees to two pivotal protocols for pexelizumab

EDEMA1 study of DX-88 meets primary endpoint

ARRY-142886 enters phase I trial for advanced cancer

A6 enters phase II trial to prevent clinical relapse in ovarian cancer patients

Second of two phase III trials for Viramidine under way

Vertex and Mitsubishi sign agreement for VX-950 in Japan and Far East

Evotec and Neuronova enter drug discovery agreement in depression, anxiety

Hemispherx submits clinical trial protocol to FDA for Alferon N

Biovail's NDA for novel dosage form of citalopram accepted for review

First quarter 2004 clinical development highlights announced by PDL

Delayed tumor progression found with atrasentan in prostate cancer

Therapeutic benefits of PT-141 plus Viagra in erectile dysfunction

Promising effects of the protease inhibitor PL-100 against resistant HIV strains

Autologous Xcellerated T-cells show antitumor efficacy in phase I/II clinical trials

Two series of mitotic kinesin KSP inhibitors claimed by Merck

Novel prostaglandin D2 antagonists under study at Merck Frosst

New HIV integrase inhibitors discovered by Pfizer researchers

Cyclodextrin complexes of opioid peptide and their use in pain and inflammation

Novel GABA-A ligands and their use covered by Merck patent

Nordic Bioscience researchers claim new GADPH and/or IAMP inhibitors

Novogen patent discloses isoflavonoid-based antiproliferative agents

New antitumor agents developed by Sanofi-Synthelabo scientists